Frodella C, Pruett S, Kaplan B
Biomedicines. 2024; 12(6).
PMID: 38927422
PMC: 11201189.
DOI: 10.3390/biomedicines12061215.
Kihara Y, Chun J
Pharmacol Ther. 2023; 246:108432.
PMID: 37149155
PMC: 10860660.
DOI: 10.1016/j.pharmthera.2023.108432.
Chen Q, Gu Y, Tan C, Sundararajan B, Li Z, Wang D
Front Nutr. 2022; 9:963662.
PMID: 36159482
PMC: 9493082.
DOI: 10.3389/fnut.2022.963662.
El-Emam M, El Achy S, Abdallah D, El-Abhar H, Gowayed M
BMC Neurosci. 2022; 23(1):11.
PMID: 35247984
PMC: 8897955.
DOI: 10.1186/s12868-022-00692-1.
Manuel A, Vasudevan M
Ann Indian Acad Neurol. 2021; 24(1):92-94.
PMID: 33911391
PMC: 8061517.
DOI: 10.4103/aian.AIAN_117_20.
A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells.
Filipczak N, Jaromin A, Piwoni A, Mahmud M, Sarisozen C, Torchilin V
Cancers (Basel). 2019; 11(12).
PMID: 31835393
PMC: 6966600.
DOI: 10.3390/cancers11121982.
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.
Rafiee Zadeh A, Askari M, Azadani N, Ataei A, Ghadimi K, Tavoosi N
Int J Physiol Pathophysiol Pharmacol. 2019; 11(4):95-104.
PMID: 31523357
PMC: 6737429.
Mitoxantrone-Surfactant Interactions: A Physicochemical Overview.
Enache M, Toader A, Enache M
Molecules. 2016; 21(10).
PMID: 27754390
PMC: 6273455.
DOI: 10.3390/molecules21101356.
Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines.
Guerriero E, Sorice A, Capone F, Napolitano V, Colonna G, Storti G
PLoS One. 2014; 9(12):e115287.
PMID: 25531443
PMC: 4274052.
DOI: 10.1371/journal.pone.0115287.
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.
Rommer P, Zettl U, Kieseier B, Hartung H, Menge T, Frohman E
Clin Exp Immunol. 2013; 175(3):397-407.
PMID: 24102425
PMC: 3927900.
DOI: 10.1111/cei.12206.
[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].
Haas J, Linker R, Hartung H, Meergans M, Ortler S, Tracik F
Nervenarzt. 2012; 83(12):1575-81.
PMID: 23203160
DOI: 10.1007/s00115-012-3612-8.
Disease modifying agents for multiple sclerosis.
Hilas O, Patel P, Lam S
Open Neurol J. 2011; 4:15-24.
PMID: 21258574
PMC: 3024587.
DOI: 10.2174/1874205X01004010015.
Chemotherapeutics in the treatment of multiple sclerosis.
Kieseier B, Jeffery D
Ther Adv Neurol Disord. 2010; 3(5):277-91.
PMID: 21179618
PMC: 3002664.
DOI: 10.1177/1756285610379885.
Animal models of multiple sclerosis--potentials and limitations.
Mix E, Meyer-Rienecker H, Hartung H, Zettl U
Prog Neurobiol. 2010; 92(3):386-404.
PMID: 20558237
PMC: 7117060.
DOI: 10.1016/j.pneurobio.2010.06.005.
Synthesis and Solid State Structure of Fluorous Probe Molecules for Fluorous Separation Applications.
Lehmler H, Telu S, Vyas S, Shaikh N, Rankin S, Knutson B
Tetrahedron. 2010; 66(14):2561-2569.
PMID: 20305832
PMC: 2840617.
DOI: 10.1016/j.tet.2010.02.018.
Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
Menge T, Weber M, Hemmer B, Kieseier B, von Budingen H, Warnke C
Drugs. 2008; 68(17):2445-68.
PMID: 19016573
DOI: 10.2165/0003495-200868170-00004.
Immunosuppressive agents in multiple sclerosis.
Neuhaus O, Kieseier B, Hartung H
Neurotherapeutics. 2007; 4(4):654-60.
PMID: 17920546
PMC: 7479677.
DOI: 10.1016/j.nurt.2007.08.003.
